Johnson Fistel Investigates Fairness of Proposed Sale of Blueprint Medicines

Core Viewpoint - Johnson Fistel, PLLP has initiated an investigation into potential breaches of fiduciary duties by the board members of Blueprint Medicines Corporation in relation to its proposed sale to Sanofi [1] Group 1: Acquisition Details - Blueprint Medicines has entered into a definitive agreement with Sanofi to sell all outstanding shares for $129.00 per share in cash, along with a non-tradeable contingent value right that could yield two milestone payments of $2 and $4 for future development and regulatory achievements related to BLU-808 [2] - The transaction agreement includes a provision that restricts Blueprint's ability to solicit or accept superior proposals, imposing a significant termination fee if the board pursues a competing bid [3] Group 2: Market Analysis - A Wall Street analyst has set a price target of $167 per share for Blueprint's common stock, which is significantly higher than the agreed transaction price of $129.00 [3]